Chicago woman returns from Blue Origin's space flight
Chicagoan Elaine Hyde fulfilled her lifelong dream of space travel, joining a six-person crew for a 10-minute Blue Origin flight.
Hyde made history as the first Australian woman and Singapore-born person to travel to space.
Blue Origin announced its next mission will feature an all-female crew, including pop star Katy Perry and CBS anchor Gayle King, launching this spring.
CHICAGO - A Chicago woman has just returned from Blue Origins' latest space flight.
What we know
Elaine Hyde, founder of Chicago Star Media, has dreamed of outer space since she was a little girl.
Her dream became a reality Tuesday when she joined a six-person crew for a 10-minute, 3-second flight to space.
"It's infused me with a new perspective of how to see life and new ideas can form. I've spent a lifetime dreaming about going to space. I've tried to imagine myself there countless times. However, going there, realizing it's real, now I've got this new energy in me to, to imagine and dream of future possibilities that could not have been done before," said Hyde.
Hyde, a dual citizen of the United States and Australia, made history as the first Australian woman and Singapore-born person to journey to space.
All-Female Crew
On Thursday, Blue Origin announced its next flight will feature an all-female crew.
Pop star Katy Perry, CBS anchor Gayle King, and Lauren Sanchez, the fiancé of Blue Origin owner Jeff Bezos, are set to be part of the team.
They will be joined by former NASA rocket scientist Aisha Bowe, civil rights activist Amanda Nguyen, and film producer Kerrianne Flynn.
The mission will mark the 11th human flight for Blue Origin's New Shepard Program and the 31st in the company's history.
What's next
So far, Blue Origin's New Shepard Program has flown 52 people to the internationally recognized boundary of space.
This all-female crew will be the first since cosmonaut Valentina Tereshkova's solo space flight in 1963.
The crew is set to launch this spring.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Chicago Tribune
5 minutes ago
- Chicago Tribune
‘The Rainmaker' review: The USA Network is back in the originals business with a John Grisham legal drama
Imagine a 1995 novel about a scrappy young lawyer whose clients are suing a health insurance company that refused to pay for a life-saving treatment, resulting in their son's death. Now imagine that novel is adapted into a TV series that decides to eliminate the health insurance angle altogether. Weird decision, all things considered! Even taking into account that the show was put in motion before anyone even knew the name Luigi Mangione. The topic is (unfortunately) as evergreen as it gets, and yet conspicuously absent here. Welcome to USA Network's 'The Rainmaker,' based on the John Grisham book, and which shoulda been a movie. Which it already was. In 1997. From writer-director Francis Ford Coppola and starring Matt Damon. If you squint, you might remember when USA was known for its 'blue skies' shows, which were light, upbeat, original series ideal for passing the time while folding laundry. I never understood why the cable channel abandoned the genre, or original programming, for that matter. But now it's dipping its toe back in. 'The Rainmaker's' basic framework actually lends itself to a TV series, of a guy fresh out of law school and desperate for a job who ends up working for an ambulance chaser named Bruiser. His new employer may be dodgy, but he also has a stronger moral compass than those pricier, snootier attorneys across town with their corporate clients and Brioni suits. In the book and the film, the kid takes the case of the aforementioned couple and it is a classic David vs. Goliath setup, with Grisham's signature propulsive energy. TV needs shows right now about defense attorneys fighting for the underdog, and while there are a couple currently built around this premise (the Kathy Bates-led 'Matlock' on CBS and 'The Lincoln Lawyer' on Netflix), that's still an anemic number. So on one hand, I welcome the 10-episode 'Rainmaker' with open arms. On the other hand, it's not very good. Too bad, because it initially captures the right Grisham-esque tone. Milo Callaghan steps into the role originated by Matt Damon, and his looks do vaguely suggest a freshly scrubbed Damon in his earlier roles. Even so, Callaghan lacks the necessary charisma that could elevate him from yet another generic white guy on screen. Rudy is meant to be the straight man, while everyone around him gets to be more colorful, but his earnest, grounding presence shouldn't be this nondescript, either. In this version, Bruiser is a woman (Lana Parrilla) and she is savvy, seasoned and jaded, working out a building that was once a taco joint. It's a nice visual joke every time the show spends time in her offices. Her paralegal is Deck (P.J. Byrne in the Danny DeVito role), who is just as jaded as Bruiser. Though initially impatient with Rudy's naivete, Deck eventually comes around to mentoring the new lawyer. The central case is similar-ish: A mother wants to sue a hospital after her son dies. She says he was admitted with the flu; the hospital says his death was the result of drug overdose. But mom insists he'd been clean for a year, there's no way this was an overdose. Rudy believes her and takes the case. Why does the show remove the story's excoriating plot about the specific venal-ness of the health insurance industry? A dogged lawyer up against this type of defendant is such a key element to the original and this pointless softening the edges is meant to appease who exactly? Media executives? Corporate sponsors? Certainly not viewers. The pilot episode is promising enough, only for subsequent episodes to devolve from there. Fundamentally, there isn't enough story. So we're stuck spending time with opposing counsel (John Slattery, doing a version of the overly confident man he's played many times before; no role has tapped his talents the way 'Mad Men' did) as well as Rudy's girlfriend, who also happens to work for opposing counsel and is being pressured to provide oppo research on Rudy's weaknesses. None of this is halfway interesting, and when the show cuts away from the central trio of Rudy, Bruiser and Deck, the series loses whatever snap it has, largely because the other characters are bland and undeveloped. Even Rudy is dull. That's a matter of the writing but also the casting. It takes more than a cornfed visage to carry a show. 'The Rainmaker' — 2 stars (out of 4) Where to watch: 9 p.m. Fridays on the USA Network (and streaming on Peacock)
Yahoo
24 minutes ago
- Yahoo
Margot Robbie Shows Off Post-Baby Glow in Curve-Hugging Mini Dress During Red Carpet Return
Margot Robbie Shows Off Post-Baby Glow in Curve-Hugging Mini Dress During Red Carpet Return originally appeared on Parade. Margot Robbie proved that Barbiecore lives on as the actress made a dazzling return to the red carpet. On Wednesday, the 35-year-old beauty joined co-star Colin Farrell during the L.A. premiere of their upcoming movie A Big Bold Beautiful Journey. The Australian actress lit up the premiere with a black figure-hugging mini dress from Stella McCartney's Resort 2026 collection. Completing the outfit, she paired the stunning LBD with strappy black sandals, adding a sleek and elegant touch to her red carpet look. As for her glam, Robbie stunned at the premiere with her iconic sleek blonde hair, channeling her inner Barbie. Meanwhile, the veteran actor opted for a more casual look, pairing a simple white T-shirt with a black cardigan and styling it with dark blue jeans and black dressy shoes. Besides wowing the public with her beauty, this also marked her first red carpet appearance since welcoming her baby boy in October with her husband Tom Ackerley. With this, she proved that motherhood hasn't slowed down her style or confidence. Fans on X couldn't help but swoon over her post-baby glow in a stunning mini dress. 'That's a MOTHER!' one wrote, praising the actress' show-stopping red carpet look. The same goes for another user who seemed in awe of the Golden Globe nominee's transformation and said, 'Sister, weren't you pregnant last time? What's your secret? How did you lose weight?' 'She never ages. Is this girl a vampire lol?' a commenter noted. 'Margot Robbie is freaking gorgeous!' a fourth user remarked. 'Yeah, I like this one. Very demure,' a fan said. Another user chimed in and commented on how she exudes 'elegance on display.' 'She's the real Barbie,' a fan mentioned. Meanwhile, the upcoming romantic fantasy movie A Big Bold Beautiful Journey is slated to hit theaters in the United States and Canada on September 19. Helmed by Kogonada, the director behind the critically acclaimed films Columbus and After Yang, the film also features Kevin Kline and Phoebe Waller-Bridge. The soon-to-be-released movie will mark the new mom's return to the big screen following the hit film Barbie in Robbie Shows Off Post-Baby Glow in Curve-Hugging Mini Dress During Red Carpet Return first appeared on Parade on Aug 21, 2025 This story was originally reported by Parade on Aug 21, 2025, where it first appeared. Solve the daily Crossword
Yahoo
34 minutes ago
- Yahoo
SINGZYME WINS 2025 AMGEN X NSG GOLDEN TICKET FOR BREAKTHROUGH BIOCONJUGATION PLATFORM
Now in its fourth year, the programme continues to empower biotech startups through ecosystem support and collaboration to advance science that serves patients. SINGAPORE, Aug. 21, 2025 /PRNewswire/ -- Singzyme, a Singapore-based biotech startup pioneering next-generation bioconjugation solutions, has been named the winner of the 2025 Golden Ticket Programme in Singapore. The award is part of a joint programme by Amgen, a U.S.-based leader in biologic medicines and NSG BioLabs, Singapore's leading provider of biotechnology co-working laboratories and offices. Now in its fourth year, the Golden Ticket Programme supports promising biotech startups by providing infrastructure, mentorship, and resources to advance scientific progress and talent development in accelerating the development of new therapies. As this year's awardee, Singzyme will receive a one-year residency at NSG BioLabs, along with access to certified BSL-2 lab facilities and networking opportunities through Amgen's community of scientific and business leaders. Singzyme was selected from a competitive pool of six finalists following an interactive pitch session reviewed by Amgen's internal scientific committee. The startup stood out for its proprietary Peptide Asparaginyl Ligase (PAL) platform, a novel site-specific conjugation technology that addresses key challenges in the manufacturing of antibody-drug conjugates (ADCs) and other complex biologics. The platform holds strong potential for enabling safer, more precise, and efficient production of next-generation targeted therapies. "Singzyme's novel platform reflects the strong scientific thinking and innovation emerging from Singapore's biotech sector," said Dr Alan Russell, Vice President for Research Biologics at Amgen. "It's encouraging to see creative approaches to longstanding challenges in bioconjugation, and we're pleased to be part of an initiative that helps spotlight and connect promising science with broader networks in the industry that aligns with Amgen's mission to deliver impactful therapies to serve patients." Ms Daphne Teo, CEO and Founder of NSG BioLabs, added, "The Golden Ticket Programme provides a valuable stepping stone for biotech startups at critical stages of their journey. As Singapore's life sciences community continues to expand, it's exciting to support companies like Singzyme as they bring their ideas to life and move closer to the clinic in Singapore's growing vibrant biotech industry." Mr Abbas Sahili, Chief Technology Officer, inventor and founding team member of Singzyme, said, "This award validates the transformative potential of Singzyme's peptide ligation technology to enable the next generation of precision medicines. The Golden Ticket is a significant recognition of our PAL platform's ability to address critical unmet needs in biologics development - not only in oncology, but across diverse modalities and disease areas." Mr Wee Kiat Tan, CEO of Singzyme, said, "With this support, we are committed to advancing our platform toward clinical applications in oncology and beyond. Through this collaboration, we will continue to strengthen our capabilities and accelerate the delivery of impactful therapies to patients worldwide." Singzyme joins a growing list of previous Golden Ticket recipients in Singapore, including Albatroz Therapeutics, VerImmune, and PairX Bio. These companies have leveraged the programme's access and visibility to further their research, raise funding, and expand partnerships. Albatroz secured US$3 million in seed funding to advance its drug development programmes, while VerImmune's recent closure of the first half of its Pre-Series A round reflects strong confidence in its platform and trajectory. Unlocking Biotech Growth Through Cross-Sector Collaboration Accelerating biotech startups takes more than breakthrough science, it requires the right mix of mentorship, infrastructure, and collaboration. This was the key message shared at a panel discussion held at the award ceremony, titled "Powering Biotech Breakthroughs: Scaling Science Through Cross-Sector Collaboration." Speakers from Amgen, ClavystBio, and the Singapore Economic Development Board (EDB) discussed how cross-sector collaboration is helping startups progress from scientific concepts to real-world applications. The discussion emphasized the importance of a dynamic ecosystem – one that offers shared infrastructure, strong talent pipelines, and access to mentorship – to support biotech ventures and enable researchers and entrepreneurs to grow and scale globally. "We are growing Singapore's biotech leadership via three key drivers – access to capital, a strong talent pool, and strategic partnerships," said Mr Chen Pengfei, Vice President for Healthcare of EDB. "Beyond a strong scientific community, a vibrant entrepreneurship ecosystem is critical to bringing innovations to market. We hope to forge more collaborations with key stakeholders including academic and biotech companies, to unlock greater growth opportunities from Singapore." For more information on Golden Ticket Programme, visit About Amgen Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions. Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average®, and it is also part of the Nasdaq-100 Index®, which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization. For more information, visit and follow Amgen on X, LinkedIn, Instagram, TikTok, YouTube and Threads. About NSG BioLabs Founded with a focus on supporting biotech innovation, NSG BioLabs offers state-of-the-art equipment, efficient operations, capital efficiency, the expertise of world-class teams and global networks to assist life sciences companies. The conducive R&D environment contains fully-equipped, certified BSL-2 laboratory and office infrastructure across 70,000 sq ft within Singapore's biomedical science clusters, Biopolis and Singapore Science Park. By providing access to high-quality infrastructure, its extensive partner network, community, and value-add benefits, NSG BioLabs ensures that companies, ranging from emerging biotech startups to multinational companies, can rapidly and efficiently execute on their cutting-edge research and development ecosystem in Singapore, leading to the innovation of revolutionary technologies and products that translate into breakthrough biotech ventures and impact for patients. For more information, visit About Singzyme Singzyme is a Singapore-based biotechnology company pioneering next-generation bioconjugation solutions for the manufacturing of antibody-drug conjugates (ADCs) and other complex biologics. Its proprietary Peptide Asparaginyl Ligase (PAL) based conjugation platform enables highly precise, efficient, and scalable site-specific conjugation of payloads to antibodies and other proteins. By combining breakthrough enzymatic technology with deep expertise in protein engineering, Singzyme empowers partners to accelerate the development of safer, more effective targeted therapies. For more information visit View original content to download multimedia: SOURCE Amgen
